The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia

Blood

Volumn 92, Issue 11, 1998, Pages 4047-4052

  Lee, Stephanie J ^a   Anasetti, Claudio ^b   Kuntz, Karen M ^b   Patten, Jonathan ^b   Antin, Joseph H ^b   Weeks, Jane C ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DONOR; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 0032403419     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.11.4047     Document Type: Article

References (30)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics, 1997. CA Cancer J Clin 47:5, 1997
2. Silberman G, Crosse MG, Peterson EA, Weston RC, Horowitz MM, Appelbaum FR, Cheson BD: Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med 331:1063, 1994
3. Marks DI, Cullis JO, Ward KN, Lacey S, Szydlo R, Hughes TP, Schwarer AP, Lutz E, Barrett AJ, Hows JM, Batchelor JR, Goldman JM: Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 119:207, 1993
4. Gratwohl A, Hermans J: Allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 17:S7, 1996
5. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc 1146:473, 1992
6. Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH: Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: A decision analysis. Ann Intern Med 127:1080, 1997
7. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH: Improved survival for patients with acute myelogenous leukemia, J Clin Oncol 13:560, 1995
8. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, Appelbaum FR, Bryant E, Chauncey TR, Sale G, Sanders JE, Storb R, Sullivan KM, Anasetti C: Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 89:4226, 1997
9. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962, 1998
10. 1997 Drug Topics Red Book. Montvale, NJ, Medical Economics, 1997
11. Allan NC, Richards SM, Shepherd PCA, UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia: UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
12. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
13. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322, 1993
14. Chronic Myeloid Leukemia Trialists' Collaborative Group: Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616, 1997
15. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New Yorks, NY, Oxford, 1996
16. McCall N: Utilization and costs of Medicare services by beneficiaries in their last year of life. Med Care 22:329, 1984
17. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J-L, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall J-F, Tanzer J: Interferon alfa-2b combined with cytarabine versus Interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223, 1997
18. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR: Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia. J Clin Oncol 125:541, 1996
19. Welch HG, Larson EB: Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 321:807, 1989
20. Dufoir T, Saux M-C, Terraza B, Marit G, Guessard S, Foulon G, Reiffers J: Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant 10:323, 1992
21. Westerman IL, Bennett CL: A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation. Stem Cells 14:312, 1996
22. Barr R, Furlong W, Henwood J, Feeny D, Wegener J, Walker I, Brain M: Economic evaluation of allogeneic bone marrow transplantation: A rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 14:1413, 1996
23. Griffiths RI, Bass EB, Powe NR, Anderson GF, Goodman S, Wingard JR: Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant 12:43, 1993
24. Pajeau TS, Waters TM, Bennett CL, Pavletic ZS, Tarantolo SR, Bishop MR: Economic analysis of allogeneic blood stem cell (BSCT) versus allogeneic bone marrow transplantation (BMT) for hematologic malignancies. Proc ASCO 16:419a, 1997
25. Hoelzer D: Hematopoietic growth factors - Not whether, but when and where. N Engl J Med 336:1822, 1997
26. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD: Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15:369, 1995
27. Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 85:1460, 1993
28. Mandelblatt JS, Fahs MC: The cost-effectiveness of cervical cancer screening for low-income elderly women. JAMA 259:2409, 1988
29. Garner TI, Dardis R: Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 25:25, 1987
30. Edelson JT, Weinstein MC, Tosteson ANA. Williams L, Lee TH, Goldman L: Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407, 1990